Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
April 25 2022 - 7:30PM
Correction: DBV Technologies to Report First Quarter 2022 Financial
Results and Recent Business Developments
Montrouge, France, April 26, 2022DBV
Technologies to Report First Quarter 2022
Financial Results and Recent Business Developments
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that the Company will
host a conference call and live audio webcast on Monday, May 2,
2022, at 5:00 p.m. ET to report first quarter 2022 financial
results and provide a corporate update.
This call is accessible via the below
teleconferencing numbers, followed by the reference ID:
89119188.
- United States: 866 374 5140
- Canada: 866 455 3403
- United Kingdom: 808 238
9813
- France: 805 102 712
A live webcast of the call will be available on
the Investors & Media section of the Company’s website:
https://www.dbv-technologies.com/investor-relations/. A replay of
the presentation will also be available on DBV’s website after the
event.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France and North American operations in Basking Ridge, New Jersey.
The Company’s ordinary shares are traded on segment B of Euronext
Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s
ADSs (each representing one-half of one ordinary share) are traded
on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Apr 2023 to Apr 2024